NCT07889492Phase 2Recruiting

A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo

Study sponsor: Edesa Biotech Inc. · EDSA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-12Estimated
Enrollment · participants80Estimated
Source updated2026-11-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Mean percent change from baseline in F-VASI at Week 28 Description: The Facial Vitiligo Area Scoring Index (F-VASI) is a validated assessment of facial vitiligo that combines the extent of facial involvement and degree of depigmentation. The primary endpoint is the mean percent change from baseline in F-VASI at Week 28. A greater reduction from baseline reflects greater improvement in facial vitiligo. Time frame: 28 Weeks. After: Measure: Mean percent change from baseline in F-VASI at Week 28 Description: The Facial Vitiligo Area Scoring Index (F-VASI) is a validated assessment of the extent and degree of depigmentation affecting the face with scores ranging from 0 to 3.5, where higher scores indicate greater facial vitiligo involvement. The primary endpoint is the mean percent change from baseline in F-VASI at Week 28. A greater reduction from baseline reflects greater improvement in facial vitiligo. Time frame: 28 Weeks.

Check registry source